Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.


Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?


Please Try Again {{ error }}

Send my password

An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Aurinia Pharmaceuticals Inc AUPH

Aurinia Pharmaceuticals Inc is a biopharmaceutical company. It provides products for patients suffering from serious diseases with a high unmet medical need. The firm is developing voclosporin, an investigational drug, for the treatment of lupus nephritis (LN), focal segmental glomerulosclerosis (FSGS), and Dry Eye Syndrome (DES). Geographically, it derives maximum revenue from the United States.

The Market Herald Price Sensitive
{{currentVideo.title}} {{currentVideo.relativeTime}}
{{story.companySymbol}} {{story.headline}}
< Previous bulletin
Next bulletin >
View modes: 

RE:More Upgrades

With all the strong upgrades I am surprised yesterday's gains did not stick today. I am hoping this goes over $30 cnd over the next few months. GLTA  rate and reply


All figures are in US$ and their upside scenario target is also raised to US$38. GLTA January 26, 2021 Aurinia Pharmaceuticals Inc. First oral more

Major Security Technology Breakthrough for RDARS

RDARS Inc. announced never-seen-before swarm technology for security drones. Their Mesh Mod V1.0 Networking enables remote Eagle Nest stations and multiple autonomous Eagle Eye drones to communicate with each other locally and offer a remote Command and Control Centre option for enhanced operations. The company anticipates 2023 to be banner year as it looks to sales in the middle of next year. more

More Upgrades

Several more analysts on the Street raised their target prices for Aurinia Pharmaceuticals Inc. ( AUPH-Q +26.04%increase   ,  AUP-T +26.71%increase   ) more

Top Gainers

Symbol/ Company Price $ Change $ Volume Data delayed at least 15 minutes, as of 25/01/2021 4:15 PM ET | All market data delayed more

Globe & Mail

They've corrected the Bloom Burton target info. GLTA Aurinia Pharmaceuticals Inc. shares surged on Monday after the Victoria-based drug developer announced it had been approved more


January 22, 2021 Aurinia Pharmaceuticals Inc.  FDA approval of voclosporin for active LN  Impact: Positive First impression Our take - We expect more


As these are upgrades, it's pretty safe to assume that Bloom Burton should have read "to US$31 from US$23. GLTA After it received approval from the U.S. Food and Drug Administration more

RE:Next mover is LMNL

Hi Reddy, I agree but would wait till end of May to buy. Good luck!  rate and reply

Thematica Insights Report and Investor Guide

Thematica Report: Investing in undervalued stocks

The Market Herald launches Thematica's latest report: Unlocking the Advantages of Undervalued Stocks. Download it today!

Next mover is LMNL

Market cap is low and they have nice pipeline! and they resubmitted a BLA in September 2020 with the FDA seeking approval to treat patients with congenital plasminogen more

RE:stock price?

I think you are too high with that stock price estimate of $35-40 Cdn.  Given the outstanding results from the trial, and the lack of current effective treatments, approval was highly likely, more

stock price?

Guys any idea about the stock price?  I am assuming 35-40 CAD?  rate and reply

RE:RE:FDA Approved with extended protection!

I think the market is fairly large, given that systemic lupus is pretty common, roughly 75 cases per 100,000 population, and somewhere around 40-60% of patients with SLE will develop lupus nephritis.& more

RE:FDA Approved with extended protection!

Anybody have an idea on how big the market is for this therapeutic? no approval for orals for LN that i knww of  rate and reply

RE:Next week Jan 22, 2021 FDA approval deadline!

No news today on the FDA approval  rate and reply

Next week Jan 22, 2021 FDA approval deadline!

Lets keep our finger cross!!  rate and reply